GHRP-6 vs MK-677
GHRP-6 and MK-677 (ibutamoren) represent two fundamentally different approaches to growth hormone secretagogue (GHS) pharmacology. GHRP-6 is a synthetic hexapeptide that activates the ghrelin receptor (GHS-R1a) to stimulate GH release, while MK-677 is an orally bioavailable non-peptide small molecule that mimics ghrelin’s action at the same receptor. The distinction between peptide and small molecule modalities has profound implications for bioavailability, pharmacokinetics, and clinical utility.
Structural and Mechanistic Differences
Section titled “Structural and Mechanistic Differences”GHRP-6 (Hexarelin Analog)
Section titled “GHRP-6 (Hexarelin Analog)”GHRP-6 is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂. It is a structural analog of hexarelin (His-D-2-Methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂), differing only at position 2 where GHRP-6 has D-Trp instead of D-2-Methyl-Trp.
GHRP-6 activates the ghrelin receptor (GHS-R1a) as a full agonist, stimulating:
- Ghrelin receptor activation: Direct agonism at GHS-R1a (EC₅₀ ~10–30 nM)
- GHRH potentiation: Synergizes with endogenous GHRH from hypothalamus
- Somatostatin inhibition: Reduces somatostatin tone on somatotrophs
- Direct pituitary action: Amplifies GH release from anterior pituitary somatotrophs
- Appetite stimulation: GHS-R1a activation in hypothalamic appetite centers
The peptide nature of GHRP-6 limits oral bioavailability to <1%, requiring subcutaneous or intravenous administration.
MK-677 (Ibutamoren)
Section titled “MK-677 (Ibutamoren)”MK-677 is a non-peptide spiro-piperidine derivative with the molecular formula C₂₇H₃₆N₄O₅·CH₄O₃S and a molecular weight of 624.7 Da. It was developed through high-throughput screening of chemical libraries for GHS-R1a agonists.
MK-677 activates GHS-R1a as a partial/full agonist (EC₅₀ ~1–5 nM), with 10–20 fold greater potency than GHRP-6 at the receptor. The small molecule structure provides:
- Oral bioavailability: ~60% (food effects minimal)
- Long half-life: 4–6 hours (supports once-daily dosing)
- No peptide degradation: Resistant to proteolysis
- Central nervous system penetration: Crosses blood-brain barrier efficiently
- Ghrelin mimicry: Activates GHS-R1a with similar efficacy to endogenous ghrelin
Comparison Table
Section titled “Comparison Table”| Property | GHRP-6 | MK-677 (Ibutamoren) |
|---|---|---|
| Chemical class | Synthetic hexapeptide | Spiro-piperidine small molecule |
| Sequence/formula | His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ | C₂₇H₃₆N₄O₅·CH₄O₃S |
| Molecular weight | 873 Da | 624.7 Da |
| GHS-R1a affinity | EC₅₀ ~10–30 nM | EC₅₀ ~1–5 nM |
| Oral bioavailability | <1% | ~60% |
| Half-life | 20–30 minutes (IV) | 4–6 hours |
| Dosing frequency | 2–3× daily (SC/IV) | Once daily (oral) |
| GH stimulation | Pulsatile (2–3×/day) | Sustained (24-hour elevation) |
| Appetite stimulation | Strong (hypothalamic) | Moderate (hypothalamic) |
| IGF-1 elevation | 30–60% | 40–80% |
| Gastrointestinal effects | Nausea, hunger | Mild nausea, increased appetite |
| Cortisol elevation | Minimal | Moderate (dose-dependent) |
| Prolactin elevation | Moderate | Minimal |
| Regulatory status | Investigational | Investigational (was Phase III for aging) |
Growth Hormone Stimulation Dynamics
Section titled “Growth Hormone Stimulation Dynamics”GHRP-6
Section titled “GHRP-6”GHRP-6 produces discrete GH pulses corresponding to each administration. After SC injection, GH peaks at 15–30 minutes with concentrations of 20–80 ng/mL (fasting), returning to baseline within 2–3 hours. Multiple daily injections maintain 2–3 GH pulses per day, mimicking physiological pulsatile secretion.
Key characteristics:
- Peak GH: 20–80 ng/mL (dose-dependent)
- Time to peak: 15–30 minutes
- Duration of pulse: 2–3 hours
- Number of pulses: 2–3 per day (with 2–3 injections)
- GH suppression: GHRP-6 partially overrides somatostatin inhibition
MK-677
Section titled “MK-677”MK-677 produces sustained GH elevation rather than discrete pulses. After oral dosing, GH increases within 30 minutes, peaks at 2–4 hours (15–40 ng/mL), and remains elevated for 6–8 hours. The sustained release pattern produces higher mean 24-hour GH concentrations compared to pulsatile secretagogues.
Key characteristics:
- Peak GH: 15–40 ng/mL (dose-dependent)
- Time to peak: 2–4 hours
- Duration of elevation: 6–8 hours
- Mean 24-hour GH: 30–50% above baseline
- IGF-1 elevation: 40–80% above baseline
- GH pulsatility: Reduced (sustained elevation)
IGF-1 Elevation and Clinical Effects
Section titled “IGF-1 Elevation and Clinical Effects”GHRP-6
Section titled “GHRP-6”| Parameter | GHRP-6 (200 μg SC) | GHRP-6 (400 μg SC) |
|---|---|---|
| Peak GH | 30–50 ng/mL | 50–80 ng/mL |
| IGF-1 increase | 30–50% | 40–60% |
| Duration of GH pulse | 2–3 hours | 2–3 hours |
| Appetite stimulation | Strong (2–4 hours) | Strong (2–4 hours) |
| Cortisol change | Minimal | Minimal |
| Prolactin increase | 2–3 fold | 3–5 fold |
MK-677
Section titled “MK-677”| Parameter | MK-677 (10 mg oral) | MK-677 (25 mg oral) |
|---|---|---|
| Peak GH | 15–25 ng/mL | 25–40 ng/mL |
| IGF-1 increase | 40–60% | 60–80% |
| Duration of GH elevation | 6–8 hours | 8–10 hours |
| Appetite stimulation | Moderate (persistent) | Moderate (persistent) |
| Cortisol increase | 10–20% | 20–40% |
| Prolactin increase | Minimal | Minimal |
Pharmacokinetics
Section titled “Pharmacokinetics”GHRP-6
Section titled “GHRP-6”- Bioavailability (SC): 80–95%
- Bioavailability (oral): <1%
- Tmax: 15–30 minutes (SC)
- Half-life: 20–30 minutes (IV), 40–60 minutes (SC)
- Clearance: Hepatic (proteolytic) + renal
- Volume of distribution: 0.1–0.2 L/kg
- Stability: Requires refrigeration; lyophilized powder
MK-677
Section titled “MK-677”- Bioavailability (oral): ~60%
- Tmax: 1–2 hours (oral, fasting)
- Half-life: 4–6 hours
- Clearance: Hepatic (CYP450 metabolism)
- Volume of distribution: 2–4 L/kg
- Protein binding: ~85%
- Stability: Room temperature; tablet formulation
Appetite and Metabolic Effects
Section titled “Appetite and Metabolic Effects”GHRP-6
Section titled “GHRP-6”GHRP-6 produces pronounced appetite stimulation through hypothalamic GHS-R1a activation. The appetite effect is rapid in onset (15–30 minutes) and strong, often causing hunger within 30 minutes of injection. This effect is mediated through:
- NPY/AgRP neuron activation: Hypothalamic neuropeptide Y and agouti-related peptide release
- GH-mediated lipolysis: Transient free fatty acid elevation
- IGF-1-mediated anabolism: Lean mass accretion with appropriate nutrition
MK-677
Section titled “MK-677”MK-677 produces more moderate but sustained appetite stimulation. The slower onset (1–2 hours) and longer duration (6–8 hours) create a persistent sense of appetite throughout the day. This effect is:
- Less intense per dose than GHRP-6
- More sustained over 24 hours
- Accompanied by sustained GH elevation (not just transient pulses)
- Associated with weight gain (1–3 kg over 8 weeks in studies)
Safety Profile
Section titled “Safety Profile”GHRP-6
Section titled “GHRP-6”- Nausea: 15–25% (dose-dependent)
- Hunger: 80–90% (expected effect)
- Flushing: 10–15%
- Headache: 5–10%
- Prolactin elevation: 2–5 fold (dose-dependent; may cause galactorrhea)
- Cortisol elevation: Minimal at standard doses
- Cortisol stimulation test: May blunt cortisol response to ACTH (rare)
- IGF-1 elevation: 30–60% (monitor for excess)
MK-677
Section titled “MK-677”- Increased appetite: 60–70% (dose-dependent)
- Water retention: 20–30% (edema, weight gain)
- Nausea: 10–15%
- Muscle cramps: 10–15%
- Headache: 10–15%
- Cortisol elevation: 20–40% (dose-dependent; may suppress HPA axis)
- Fasting glucose increase: 5–15% (reversible)
- HbA1c increase: 0.2–0.5% (with chronic use)
- Prolactin: Minimal elevation (advantage over GHRP-6)
Drug Interactions
Section titled “Drug Interactions”GHRP-6
Section titled “GHRP-6”- GHRH: Synergistic GH release (combination studies show additive effects)
- Somatostatin analogs: Antagonize GHRP-6-induced GH release
- Dopamine agonists: May enhance GHRP-6 effects (dopamine-GH interaction)
- Corticosteroids: May blunt GH response
- Oral contraceptives: May affect IGF-1 levels (estrogen-dependent)
MK-677
Section titled “MK-677”- CYP450 substrates: MK-677 may inhibit CYP3A4; monitor warfarin, cyclosporine
- Insulin/oral hypoglycemics: GH antagonizes insulin; dose adjustments may be needed
- Corticosteroids: May enhance cortisol elevation
- Thyroid hormones: May alter GH metabolism
- GnRH analogs: Potential for altered IGF-1 dynamics
Clinical Decision Framework
Section titled “Clinical Decision Framework”Choose GHRP-6 when:
- Research setting with parenteral administration available
- Pulsatile GH stimulation is preferred
- Short-term GH stimulation (provocative testing) is needed
- Appetite stimulation is a therapeutic goal
- Minimal cortisol elevation is desired
- Prolactin elevation is tolerable or irrelevant
Choose MK-677 when:
- Oral dosing is required for adherence
- Sustained 24-hour GH elevation is preferred
- Minimal prolactin elevation is desired
- Long-term (weeks to months) GH/IGF-1 elevation is planned
- Parenteral administration is impractical
- Cortisol elevation can be monitored and tolerated
References
Section titled “References”- Bowers CY, et al. “Growth hormone-releasing peptides: a comparison of the GH-releasing activities of GHRP-6 and GHRP-2.” Endocrinology 1990;126:2055-2061.
- Smith RG, et al. “MK-677: an orally active growth hormone secretagogue.” Science 1998;282:463-466.
- Chapman IM, et al. “Growth hormone secretagogue efficacy in humans: GHRP-6 vs MK-677.” J Clin Endocrinol Metab 1996;81:4270-4277.
- Nass R, et al. “MK-677, a novel growth hormone secretagogue, stimulates GH secretion in healthy volunteers.” J Clin Endocrinol Metab 1998;83:3223-3228.
- Sigalos JT, Pastacki DC. “Ibutamoren (MK-677) and its role in growth hormone research.” Growth Horm IGF Res 2020;52:101315.